Figure 2 shows temporal trends in outcomes for heart failure patients with reduced ejection fraction after quadruple therapy. Graph A: 30-day follow-up; Graph B: 12-month. Both graphs compare cumulative incidence % between July-Sept text@1 and Oct-Dec text@2.

In US practice, older adults hospitalized for #HFrEF and prescribed quadruple therapy still face 1 in 5 risk of death and 1 in 4 risk of heart failure rehospitalization at 1 year, with high associated health care costs.

ja.ma/4cTH9mg

Nomogram-Based Prediction of Mortality after Cardiac Resynchronization Therapy in Patients with Heart Failure A predictive nomogram to improve risk stratification after cardiac resynchronization therapy (CRT) in patients with heart failure.

This study builds a bedside #nomogram including NOAF, age, NYHA class, sodium, platelets, and #GDMT to predict post-CRT mortality in #HFrEF, showing high accuracy & enabling personalized risk stratification, follow-up, & therapy optimization to improve outcomes.

#OpenAccess: tinyurl.com/2c6u2rk2

Figure 2 shows temporal trends in clinical outcomes for heart failure patients with reduced ejection fraction. Graph A: 30-day follow-up, Graph B: 12-month follow-up. Bars compare cumulative incidence in July 2021-Sept 2022 to Oct 2022-Dec 2023.

Among older patients hospitalized for #HFrEF, prescription of quadruple medical therapy at discharge was associated w/ a 1-year mortality of 19% and heart failure rehospitalization rate of 26%, w/ median health care costs of nearly $28,000 per patient.

ja.ma/4akLpJT

Managing HF Across the Spectrum: This interactive online course offers practical tools to assess risk, classify HF phenotypes, & apply GDMT through an interprofessional care lens. Learn how to tackle pivotal issues in #HFrEF, & more. 👇

🔖 https://bit.ly/3O8JvDp

#ACCEd #CardioSky #MedSky

Figure shows temporal trends in clinical outcomes for heart failure patients with reduced ejection fraction. Two bar graphs compare cumulative incidence (%) at 30-day & 12-month follow-ups for all-cause mortality, HF hospitalization, & combined outcomes.

Among older patients hospitalized for #HFrEF, prescription of quadruple medical therapy at discharge was associated with a 1-year mortality of 19% and heart failure rehospitalization rate of 26%, with median health care costs of nearly $28,000 per patient.

ja.ma/4t1I8ql

Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF

Niveles elevados de LDH se asocian con un riesgo elevado de variables clínicas en la insuficiencia cardíaca con fracción de eyección reducida #HFrEF. #LDH www.jacc.org/doi/10.1016/...

JAMA study: treatments for heart failure(HF) effective for HF with reduced ejection fraction due to Chagas disease? 922 patients randomized. Sacubitril/valsartan: 23.8% death from cardiovascular causes. Enalapril: 25.4%. NT-proBNP change: -30.6% vs -5.5%.

RCT: In patients with #Chagas-related #HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.

ja.ma/4aNRXBs

Vericiguat in Heart Failure: Insights From the VICTOR Trial - American College of Cardiology

The VICTOR study results complement those of the VICTORIA by extending the evidence base for vericiguat in a contemporary lower-risk, well-treated ambulatory #HFrEF population.

Explore more insights from the VICTOR trial ➡️ https://bit.ly/4blPC0O #HeartFailure

JAMA study: Sacubitril/valsartan vs. enalapril for heart failure due to Chagas disease. 922 patients randomized. Findings: Sacubitril/valsartan showed a greater reduction in NT-proBNP compared to enalapril. No significant difference in death/hospitalization.

RCT: In patients with #Chagas-related #HFrEF, sacubitril/valsartan did not reduce rates of cardiovascular death or heart failure hospitalization compared with enalapril.

ja.ma/4aex1mK

How is your team addressing chronic disease education? Share your strategies! 👇

8/7
#MoreThanAJournal #howwehospitalist #HeartFailure #PatientEducation #HospitalMedicine #GDMT #HFpEF #HFrEF #MedTwitter

Heart failure with reduced ejection fraction.

www.thelancet.com/journals/lan...

@thelancet.com
#CardioSky #HFrEF #HeartFailure

📢 POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With #HFrEF

Read more: https://bit.ly/4hV9byv

#AHA25 #HeartFailure #CardioSky #MedSky

ACC CardiaCast: In this episode, Drs. @mkittlesonmd.bsky.social & Estefania Oliveros Soles discuss the biggest challenges in #HFrEF and #HFpEF, focusing on hyperkalemia (uncommon) and hypokalemia (associated with higher mortality).

Tune in here ➡️ https://bit.ly/46Tt8lk #HeartFailure #CardioSky

Management of primary central nervous system lymphoma and coexisting heart failure with reduced ejection fraction: a narrative review Explore current treatments for primary central nervous system lymphoma, including those involving high-dose methotrexate, and their implications for patients with heart failure with reduced ejection…

Explore current treatments for primary central nervous system lymphoma, including those involving high-dose #methotrexate, and their implications for patients with #HFrEF.

👉https://buff.ly/hHicXoQ

#NeuroSky #PCNSL

Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials Vericiguat reduced the risk of hospitalisation for heart failure and cardiovascular death in patients with HFrEF across a broad range of clinical severity, including those receiving contemporary guide...

Vericiguat reduce riesgo de hospitalización por insuficiencia cardíaca y muerte por causas CV en pac c/insuficiencia cardíaca c/fracción de eyección reducida, independientemente de la gravedad, incluyendo los q reciben terapia médica según guías #vericiguat #HFrEF www.thelancet.com/journals/lan...

Digitoxin in Patients with Heart Failure and Reduced Ejection Fraction | NEJM The therapeutic efficacy of the cardiac glycoside digitoxin in patients with heart failure and reduced ejection fraction is not established. In this international, double-blind, placebo-controlled ...

En pacientes con insuficiencia cardíaca y fracción de eyección reducida que reciben terapia médica según las guías, el tratamiento con digitoxina reduce el riesgo de muerte por cualquier causa o ingreso por empeoramiento de la insuficiencia cardíaca #digitoxin #HFrEF www.nejm.org/doi/full/10....

In #HFrEF, quadruple therapy (ARNi, β-blockers, MRA, #SGLT2i) improves survival. Adding #vericiguat may offer a modest ~0.7-year gain, though findings are exploratory, as they are derived from a secondary endpoint of a single trial https://bit.ly/4mE83Rp

#JACC #ESCCongress #WCCardio

When to downtitrate/stop #GDMT in #HFrEF? Prof #BiykemBozkurt 🫀

📍Recovered: individualized, may consider de-escalation
📍Improving: continue/optimize
📍Persistent: escalate, close FU/referral
📍Refractory: ⬇️doses/advanced tx

⚠️No solid data for routine withdrawal

#ESCCongress @escardio.bsky.social

🔥 long awaited data on digitoxin💊 in chronic #HFrEF
✔️ significant reduction in death or first hospital admission for worsening heart failure
✔️ treatment with digitoxin was safe
nejm.org/doi/full/10.10…
➡️ more data on digoxin to follow next year #DECISIONtrial @escardio.bsky.social

🚨 #HFpEF ≠ #HFrEF! Turns out, the #immunesystem knows the difference. We profiled #immunecells in HFpEF patients (scRNA-seq) & mice-showing conserved inflammatory programs & the therapeutic potential of #NO₂-OA. 👉 doi.org/10.1161/CIRC...

#SOLOISTWHF is an example of sheermarketing. Enlist a highly diverse cohort of 79% HFrEF and 21% #HfrEF then market the results as positive for HfpEF. A closer look at the CI reveals an imprecise underpowered & completely useless trial. Pure marketing.

Free Open Access Comparison Chart: Some Drugs for HFrEF bit.ly/43a4PxF

#HeartFailure #HFrEF #FOAMed

Read our latest issue, Drugs for Chronic Heart Failure: bit.ly/44E8FjQ

The Comparison Chart: Some Drugs for HFrEF is freely accessible.
#Heartfailure #FOAMed #HFrEF #HFpEF

【診断後早期のGDMT開始 [可能例】でHFrEFの転帰改善/ ESC HF

デンマークHFレジストリ、HFrEF 46,816例観察：

・診断４週間以内のガイドライン推奨薬「3~4」剤「開始」で「非開
　始」に比べ、１年間死亡の補正後HRは0.65 [95CI：0.55-0.78]、３
　年間なら0.67 [0.59-0.76]。
・一方、「1~2」剤開始でも0.73 [95%CI：0.61-0.86]と0.75 [0.66-
　0.86]。
・CV死亡も同様。

x.gd/OA954

#HFrEF #GDMT

🚦Latest @medscape.com Primary Care #hack is live!

🔥Paired #hacks covering the diagnosis & management of #HFrEF & #HFpEF in primary care

PDF download link in comments 👇🏾

@pharmrj.pharmsky.app @goggledocs.bsky.social @hpillminster.pharmsky.app

Growth Hormone Replacement Therapy in Heart Failure With Reduced Ejection Fraction: A Randomized, Double-Blind, Placebo-Controlled Trial

New study in #JACCHF on growth hormone (GH) replacement in patients with GH deficiency + #HFrEF
🔸 Improved exercise capacity + #QoL in GH replacement vs controls
🔸 Impetus here to screen for GH more, consider in those with residual symptoms despite #GDMT

📎: www.jacc.org/doi/10.1016/... #CardioSky

Awesome talk from @mkittlesonmd.bsky.social on #HF in women from #GDMT to #VAD and #transplant #HFpEF #HFrEF
@womensheart.bsky.social
#CardioSky

Direct-to-Physician Marketing and Uptake of OMT for #HFrEF

📌60% of general & 50% of #AHF cardiologists received ARNI/#SGLT2i marketing (2019-2021)

📌#ARNI meals in 2020 led to +43% to +109% higher prescribing in 2021 for general cardiologist

#HeartFailure #GDMT
www.jacc.org/doi/10.1016/...

Association of body composition with left ventricular remodeling and outcomes in diabetic heart failure with reduced ejection fraction: assessment of sarcopenic obesity using cardiac MRI - Cardiovascu... Background Obesity is common in the heart failure (HF) population and is regarded as an important risk factor for developing HF. Greater skeletal muscle mass has shown to be the underlying protective ...

Obesidad sarcopénica es un fenotipo de alto riesgo potencial c/emodelado ventricular izq adverso y mal resultado clínico en pac diabéticos c/insuficiencia cardíaca con fracción de eyección reducida q pueden requerir más atención #sarcopenic #obesity #HFrEF cardiab.biomedcentral.com/articles/10....

MRA: A powerhouse for the heart & kidneys! 🛡️❤️🫘🩺

From #HeartFailure to #CKD & #Dialysis—MRAs bridge the gap between CV & renal benefits! Game-changer for #HFrEF, post-MI & #ESRD patients.

📖 doi.org/10.1097/FJC.... (2025)

#Nephrology #Cardiology #MRAs #NephPearl